Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress
Pharmaceutical Investing New Data on KEYTRUDA® Plus LENVIMA® Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting
Psychedelics Investing BRAXF FINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Braxia Scientific Corp. f/k/a Champignon Brands Inc. Investors with Losses to Secure Counsel Before Important June 9 Deadline in Securities Class Action - BRAXF, SHRMF
Results From Phase 2 CodeBreaK 100 Show LUMAKRAS Is The First And Only KRAS G12C Inhibitor With Overall Survival Data
Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation
Psychedelics Investing SHRMF Looming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Champignon Brands Inc. Shareholders of Class Action and Lead Plaintiff Deadline: June 9, 2021
Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain MetastasisÂ
